Copyright @ 2018 kelun.com | 蜀ICP备05021377号 | Powered by www.300.cn | Download | Public Welfare Cause |
Global Market
Global Market
Kelun has been dedicated to expanding the global market and actively implemented an international strategy. Its main products have achieved scaled exports, enjoying a good reputation in over 50 countries and territories. In 2018, Kelun became the first Chinese-funded IV solution manufacturer that passed Japan PMDA GMP inspection and exported to Japan. In 2024, Kelun successfully obtained the GMP certification from the Brazilian ANVISA, which shall greatly facilitate Kelun's entry into Brazil, alongside other PIC/S member countries and emerging markets.
Meanwhile, Kelun has established overseas factories in several key regions worldwide. Kelun-Kazpharm, established in Kazakhstan and put into production in 2014, is a significant strategic move by the company to align with the “The New Silk Road Economic Belt” national strategy, which marked a solid step in Kelun’s foreign direct investment. In 2019, Kelun established Kelun Lifesciences (Private) Limited and invested in Celogen Lanka (Private) Limited in Sri Lanka, strengthening the company’s development in the South Asia market.
In 2024, Celogen Lanka became the first pharmaceutical enterprise that passed EU GMP inspection in Sri Lanka, and shall achieve exportation to EU markets. Kelun will continuously optimize global resource allocation, enhance product and service quality, and promote the company's high quality and sustained growth in the global market.